Weil Company Inc. Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)

Weil Company Inc. lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,803 shares of the biotechnology company's stock after selling 2,002 shares during the period. United Therapeutics makes up 1.4% of Weil Company Inc.'s investment portfolio, making the stock its 17th largest position. Weil Company Inc.'s holdings in United Therapeutics were worth $4,230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Janney Montgomery Scott LLC grew its position in United Therapeutics by 2.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,960 shares of the biotechnology company's stock worth $2,058,000 after acquiring an additional 201 shares during the last quarter. SG Americas Securities LLC grew its position in United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company's stock worth $3,288,000 after acquiring an additional 9,133 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in United Therapeutics by 17.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 4,640 shares of the biotechnology company's stock worth $1,066,000 after acquiring an additional 699 shares during the last quarter. Forsta AP Fonden grew its position in United Therapeutics by 14.5% during the 1st quarter. Forsta AP Fonden now owns 8,700 shares of the biotechnology company's stock worth $1,999,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Sei Investments Co. grew its position in United Therapeutics by 3.2% during the 1st quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company's stock worth $8,562,000 after acquiring an additional 1,149 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 96,422 shares of company stock valued at $35,251,428 over the last 90 days. Company insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on UTHR shares. Jefferies Financial Group raised their target price on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. TD Cowen lifted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Price Performance

Shares of UTHR traded down $9.56 during trading hours on Monday, hitting $400.44. The stock had a trading volume of 442,700 shares, compared to its average volume of 464,767. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The firm has a market capitalization of $17.88 billion, a PE ratio of 18.01, a PEG ratio of 1.20 and a beta of 0.56. The stock has a fifty day moving average price of $359.20 and a 200 day moving average price of $323.38.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the company posted $5.38 earnings per share. United Therapeutics's revenue was up 22.9% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.